Synaffix B.V., a biotechnology company focused on commercializing its antibody-drug conjugates (ADCs) technology, has entered into a technology agreement with MacroGenics, Inc., a biopharma company developing monoclonal antibody-based therapeutics for the treatment of cancer.   Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads (...